339 related articles for article (PubMed ID: 30328061)
21. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
[TBL] [Abstract][Full Text] [Related]
22. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland.
Oksi J; Aalto A; Säilä P; Partanen T; Anttila VJ; Mattila E
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1947-1952. PubMed ID: 31359254
[TBL] [Abstract][Full Text] [Related]
23. Bezlotoxumab for the Prevention of
Chahine EB; Cho JC; Worley MV
Consult Pharm; 2018 Feb; 33(2):89-97. PubMed ID: 29409575
[TBL] [Abstract][Full Text] [Related]
24. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.
Luo Y; Lucas AL; Grinspan AM
Dig Dis Sci; 2020 Apr; 65(4):1125-1133. PubMed ID: 31493042
[TBL] [Abstract][Full Text] [Related]
25. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
26. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.
Baro E; Galperine T; Denies F; Lannoy D; Lenne X; Odou P; Guery B; Dervaux B
PLoS One; 2017; 12(1):e0170258. PubMed ID: 28103289
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
[TBL] [Abstract][Full Text] [Related]
29. ▼ Bezlotoxumab for prevention of recurrence of Clostridium difficile infection.
Drug Ther Bull; 2018 May; 56(5):57-60. PubMed ID: 29760164
[No Abstract] [Full Text] [Related]
30. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
Cornely OA; Watt M; McCrea C; Goldenberg SD; De Nigris E
J Antimicrob Chemother; 2018 Sep; 73(9):2529-2539. PubMed ID: 29800295
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines.
Rajasingham R; Enns EA; Khoruts A; Vaughn BP
Clin Infect Dis; 2020 Feb; 70(5):754-762. PubMed ID: 31001619
[TBL] [Abstract][Full Text] [Related]
32. Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review.
Kaako A; Al-Amer M; Abdeen Y
Anaerobe; 2019 Feb; 55():112-116. PubMed ID: 30521856
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent
Yee KL; Kleijn HJ; Kerbusch T; Matthews RP; Dorr MB; Garey KW; Wrishko RE
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455246
[TBL] [Abstract][Full Text] [Related]
34. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
Watt M; McCrea C; Johal S; Posnett J; Nazir J
Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.
Mohamed MFH; Ward C; Beran A; Abdallah MA; Asemota J; Kelly CR
J Clin Gastroenterol; 2024 Apr; 58(4):389-401. PubMed ID: 37395627
[TBL] [Abstract][Full Text] [Related]
36. Genetic Association Reveals Protection against Recurrence of
Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
mSphere; 2020 May; 5(3):. PubMed ID: 32376702
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection.
Varier RU; Biltaji E; Smith KJ; Roberts MS; Jensen MK; LaFleur J; Nelson RE
Clin Microbiol Infect; 2014 Dec; 20(12):1343-51. PubMed ID: 25366338
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
Ford DC; Schroeder MC; Ince D; Ernst EJ
Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
[TBL] [Abstract][Full Text] [Related]
39. Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience.
Olmedo M; Kestler M; Valerio M; Padilla B; Rodríguez González C; Chamarro E; Machado M; Álvarez-Uría A; Alcalá L; Muñoz P; Bouza E
Rev Esp Quimioter; 2022 Jun; 35(3):279-283. PubMed ID: 35279984
[TBL] [Abstract][Full Text] [Related]
40. Zinplava Tackles Toxins Of Hard-to-Treat C. Difficile.
Morrow T
Manag Care; 2017 Jan; 26(1):30-31. PubMed ID: 28121597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
